COChristina Ong

Christina Ong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christina Ong has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    International Cross-Sectional Survey among Healthcare Professionals on the Management of Cow’s Milk Protein Allergy and Lactose Intolerance in Infants and Children

    by J Armando Madrazo, Fawaz Alrefaee, Anjan Chakrabarty, Julia C. de Leon, Lanlan Geng, Sitang Gong, Ralf G. Heine, Anette Järvi, Jarungchit Ngamphaiboon, Christina Ong, et al.

    Madrazo JA, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 May;25(3):263-275. https://doi.org/10.5223/pghn.2022.25.3.263


  • Open Access

    Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn’s disease

    by Christina Ong, Poh Ting Lim, Veena Logarajah, Maria Janelle Liwanag, Bi Xia Ang, Yuqin Cher, Fang Kuan Chiou, Ajmal Kader

    Exclusive enteral nutrition (EEN) is as effective as corticosteroids in inducing remission in children with Crohn’s disease (CD). However, over 50% of these children relapse by 12 months of diagnosis. Thiopurines are commonly prescribed as maintenance therapy for CD, but evidence for its efficacy is controversial. Data on the effectiveness of EEN in Southeast Asian (SEA) children with CD is scarce. This study aims to evaluate the efficacy of EEN induction therapy in a cohort of SEA children with newly diagnosed CD. The secondary aim was to evaluate concomitant early azathioprine (EAZ) use in determining remission rate at 6 and 12 months. Case records of all children with newly diagnosed CD from 2011 to 2014 were reviewed and relevant demographic as well as clinical data were extracted. The primary outcome measure was the number of patients who completed EEN induction therapy and achieved remission (Paediatric Crohn’s Disease Activity Index; PCDAI≤10). Factors influencing duration of remission were evaluated in particular early azathioprine (EAZ) defined as starting azathioprine within one month of diagnosis versus late azathioprine (LAZ) use. Forty children with newly diagnosed CD were identified. Thirty-three children: 67% boys, median age 13y (range 3–17) completed 8 weeks of EEN induction therapy and 91% achieved remission. Significant improvements were seen in PCDAI scores (32.7 ± 9.2 to 4.2 ± 5.1; p < 0.001), mean BMI z-score (− 1.38 ± 1.57 to − 0.82 ± 1.27; p = 0.004) and baseline inflammatory markers: Erythrocyte Sedimentation Rate (51.6 ± 30.1 mm/h to 13.3 ± 7.1 mm/h; p < 0.0001) C-Reactive Protein (44.6 ± 51.0 mg/L to 5.2 ± 7.6 mg/L; p = 0.001), Albumin (30.7 ± 7.5 g/L to 38.7 ± 3.9 g/L; p < 0.0001), Platelets (464 ± 161 × 109 to 370 ± 111 × 109; p < 0.0001),. Early azathioprine initiation was associated with a remission rate of 80 and 73% at 6 and 12 months respectively. Remission was also maintained for longer duration in EAZ vs LAZ groups (p = 0.048). EEN effectively induces remission in this cohort of SEA children with newly diagnosed CD. Early initiation of thiopurine with EEN induction therapy is effective in maintaining steroid-free remission for at least one year.


  • Rapid rise in the incidence and clinical characteristics of pediatric inflammatory bowel disease in a South–East Asian cohort in Singapore, 1994–2015

    by Christina Ong, Marion M Aw, Maria J Liwanag, Seng H Quak, Kong B Phua

    OBJECTIVES: Epidemiological studies on pediatric‐onset inflammatory bowel disease (PIBD) are scarce in South–East Asia (SEA). This study aimed to evaluate the incidence trend and clinical characteristics of PIBD in a SEA cohort in Singapore over 22 years (1994–2015).METHODS: Case records of PIBD ≤18 years from the only two tertiary pediatric hospitals in Singapore were reviewed. The mean annual incidence (MAI) of PIBD was calculated based on Singapore's age‐specific population data.RESULTS: Overall MAI of PIBD was 1.26 per 100 000 (95% confidence interval [CI] 0.56–1.96). During the first decade (1994‐2004) MAI was 0.23 per 100 000 (95% CI 0.08–0.39); this rose almost 10‐fold to 2.28 per 100 000 (95% CI 1.15–3.41) during the second decade (2005–2015). Linear regression analysis showed significant increase in MAI over the 22‐year period (r = 0.826, P < 0001). Of the 228 patients, 61.0% had Crohn's disease (CD), 30.3% ulcerative colitis and 8.7% IBD‐unclassified, with a mdian age at diagnosis of 10.47 years and a male predominance (58.3%); 37.7% of them aged <10 years at diagnosis and 17.5% were very early‐onset IBD. In CD, 27.3% had stricturing and/or penetrating disease and 21.6% were with perianal disease. Indians had a disproportionately high representation while positive family history was rare (1.3%).CONCLUSIONS: Although PIBD is uncommon in Singapore, its incidence has risen dramatically over recent decades. A younger age of disease onset and higher proportions of perianal and stricturing/penetrating diseases suggest more aggressive disease than in Western data.


  • Serologic Responses After Hepatitis B Vaccination in Preterm Infants Born to Hepatitis B Surface Antigen–Positive Mothers

    by Christelle Xian-Ting Tan, Si-Min Chan, Le-Ye Lee, Christina Ong, Kong-Boo Phua, Marion Margaret Aw, Sharon Saw, Guan-Huei Lee, Franco Wong, Koh-Cheng Thoon

    The Advisory Committee on Immunization Practices (ACIP) recommends a 4-dose vaccination schedule for preterm low birth weight infants (10 IU/L (Abbott Architect) at 9 months chronologic age. A total of 24 preterm infants were recruited. Four had a birth weight <2kg. Of 23 surviving infants, all were negative for HBsAg. One baby (4.5%) did not achieve adequate vaccine response. All 4 infants with birth weight <2kg achieved seroprotective values. The current ACIP recommended vaccination schedule results in adequate antibody responses in preterm infants of HBsAg positive mothers.


  • Open Access

    Dengue Fever Associated Liver Failure

    by Joanne Mui Ching Tan, Natalie Woon Hui Tan, Koh Cheng Thoon, Chia Yin Chong, Christina Ong

    Background: Dengue fever is common in Southeast Asia although liver failure is a rare complication with up to 50% mortality rate reported in children. Objective: To evaluate the characteristics and treatment outcome of dengue fever associated liver failure (DFALF) in a case series of 4 paediatric patients. DFALF was defined as INR>2, regardless of the presence or absence of encephalopathy or INR>1.5 not corrected by Vitamin K in the presence of clinical hepatic encephalopathy, during the course of concurrent dengue infection. Material and methods: Patients with DFALF, admitted to a tertiary paediatric centre in Singapore over a 6 year period (January 2009-December 2015) were identified from the Gastroenterology and Infectious Disease databases. Case records were retrospectively reviewed. Results: Four patients, all boys, age 5 months to 6 years, presented at the acute febrile phase of illness with Dengue Shock Syndrome (severe dengue). Aspartate Transaminase (AST) and Alanine Transaminase (ALT) peaked at day 4-7: median (± 2SD) peak ALT 1871.5 ± 917 u/L, whereas median peak AST 7802.5 ± 5453.8 u/L. Median peak International Normalised Ratio ( INR ), ammonia, lactate were 2.9 ± 1.6, 106 ± 144.6 umol/L, and 7.4 ± 8.4 mmol/L respectively. All patients had hepatomegaly and mild conjugated hyperbilirubinaemia, with median peak total bilirubin 73.5 ± 36.9 umol/L. Two patients received N-Acetylcysteine. One patient received intravenous dexamethasone for dengue associated hemophagocytic lymphohistiocytosis. All recovered fully with supportive treatment based on a well-designed acute liver failure protocol, which comprised of intensive care monitoring, correction of coagulopathy and hypoglycaemia, empirical broad spectrum antibiotic coverage and anti-fungal prophylaxis, gastrointestinal haemorrhage prophylaxis with a histamine-2 receptor antagonist, proton pump inhibitor or sucralfate, and lactulose to reduce hyperammonaemia. Liver function significantly improved (ALT<500 u/L) at a median of 6.5 ± 2 days from onset of liver failure. INR normalized (INR<1.1) at a median of 13.5 ± 6 days of illness. Conclusion: Patients with DFALF can achieve normalisation of liver function and full recovery with early supportive treatment.

  • Risk of Major Abdominal Surgery in an Asian Population-based Crohnʼs Disease Cohort

    by Anuradha Pandey, Ennaliza Salazar, Christopher S. C. Kong, Wee Chian Lim, Jeannie Ong, David E. H. Ong, Christina Ong, Marion Aw, Eric Wee, Sai Wei Chuah, et al.

    Crohn's disease (CD) is increasing in incidence and prevalence in Asia, but there is a paucity of population-based studies on risk factors for surgery in Asian patients with CD. This will be useful to identify patients who may benefit from top-down treatment. This study describes the rates of abdominal surgery and identifies associated risk factors in Singaporean patients with CD.